Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

被引：23

作者：

Schuler, Martin H.

Ascierto, Paolo A.

de Vos, Filip Yves Francine Leon

Postow, Michael Andrew

Van Herpen, Carla M. L.

Carlin, Matteo S.

Sosman, Jeffrey A.

Berking, Carola

Long, Georgina V.

Weise, Amy

Gutzmer, Ralf

Kaatz, Martin

McArthur, Grant A.

Schwartz, Gary

Daud, Adil

Maharry, Kati

Yerramilli-Rao, Padmaja

Zimmer, Lisa

Bozon, Viviana

Amaria, Rodabe Navroze

机构：

[1] Univ Hosp, West German Canc Ctr, Essen, Germany

[2] Ist Nazl Tumori Fdn G Pascale IRCCS, Naples, Italy

[3] Univ Med Ctr Utrecht, Canc Ctr, Dept Med Oncol, Utrecht, Netherlands

[4] Weill Cornell Med Coll, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY USA

[6] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[7] Westmead & Blacktown Hosp, Sydney, NSW, Australia

[8] Melanoma Inst Australia, Sydney, NSW, Australia

[9] Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL USA

[10] Univ Hosp Munich LMU, Dept Dermatol & Allergy, Munich, Germany

[11] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[12] Karmanos Canc Inst, Detroit, MI USA

[13] Hannover Med Sch, Skin Canc Ctr Hannover, Hannover, Germany

[14] SRH Wald Klinikum Gera GmbH, Gera, Germany

[15] Peter MacCallum Canc Ctr, Melbourne, Australia

[16] Columbia Coll Phys & Surg, New York, NY USA

[17] UCSF Helen Diller Family Comprehens Canc Ctr, Melanoma Clin Res, San Francisco, CA USA

[18] Array BioPharma Inc, Boulder, CO USA

[19] Novartis Inst BioMed Res, Cambrdige, MA USA

[20] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.9519

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9519

引用

页数：5

共 50 条

[41] A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma
Patel, S. P.
Hodi, F. S.
Gabrilovich, D.
Chin, M.
Gibney, G.
Goldsberry, A.
Gonzalez, R.
Hurt, J.
Markowitz, J.
Whitman, E.
Meyer, C.
Salama, A.
ANNALS OF ONCOLOGY, 2017, 28
[42] Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.
Vugmeyster, Yulia
Wilkins, Justin
Harrison-Moench, Eleanor
Geng, Wanping
Koenig, Andre
Cao, Liang
Gulley, James L.
Dussault, Isabelle
Khandelwal, Akash
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[43] Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
Ribas, A.
Gonzalez, R.
Drabick, J.
Kummar, S.
Agarwala, S.
Nemunaitis, J.
Coffman, R.
Berman, C. J.
Schmidt, E.
Chartash, E.
Guiducci, C.
Candia, A.
Janssen, R.
ANNALS OF ONCOLOGY, 2016, 27
[44] Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study
Wei, Xiaoting
Zou, Zhengyun
Zhang, Weizhen
Fang, Meiyu
Zhang, Xiaoshi
Luo, Zhiguo
Chen, Jing
Huang, Gang
Zhang, Peng
Cheng, Ying
Liu, Jiwei
Liu, Jiyan
Zhang, Junping
Wu, Di
Chen, Yu
Ma, Xiaobiao
Tian, Hongqi
Jia, Zhongwei
Guo, Jun
Si, Lu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Determination of a recommended Phase 2 dose (RP2D) for SRF388, a first-in-class IL-27-blocking antibody, in patients with advanced solid tumors
Hill, Jonathan A.
White, Kerry F.
Rausch, Matthew
Chung, Jou-Ku
Patnaik, Amita
Naing, Aung
Morgensztern, Daniel
Mantia, Charlene M.
Tannir, Nizar M.
Smith, Lon S.
Bowers, Beth
Alika, Alex
Harshman, Lauren C.
Lee, Benjamin H.
CANCER RESEARCH, 2022, 82 (12)
[46] Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3)
Piha-Paul, Sarina A.
Call, Justin A.
Spira, Alexander I.
Bartolome, Jorge
de Miguel, Maria J.
Du, Yangchun
DiLea, Clifford
Panchabhai, Sonali
Lakhani, Nehal J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Toxicity remains the key determinant of recommended phase II dose (RP2D) of anticancer agents despite increasing use of non-toxicity endpoints
Hansen, A.
Cook, N.
Eitan, A.
Siu, L.
Razak, A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S73 - S73
[48] A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer
Goel, S.
Spring, L.
Rees, R.
Andrews, C.
Tahara, R. K.
Mayer, E. L.
Bardia, A.
Winer, E. P.
Tolaney, S. M.
CANCER RESEARCH, 2019, 79 (04)
[49] A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
El-Khoueiry, A.
Gitlitz, B.
Cole, S.
Tsao-Wei, D.
Goldkorn, A.
Quinn, D.
Lenz, H. J.
Nieva, J.
Dorff, T.
Oswald, M.
Berg, J.
Menendez, X.
Karakozian, K.
Krasnoperov, V.
Liu, R.
Thomas, J.
Groshen, S.
Gill, P.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
[50] Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
Atkins, Michael B.
Reiney, Ragini
Sznol, Kudchadkar Mario
McDermott, David F.
Lotem, Michal
Schachter, Jacob
Wolchok, Jedd D.
Urba, Walter John
Kuzel, Timothy
Schuchter, Lynn Mara
Slingluff, Craig L.
Ernstoff, Marc S.
Fay, Joseph W.
Friedlander, Philip Adam
Gajewski, Thomas
Zarour, Hassane M.
Rotem-Yehudar, Rinat
Sosman, Jeffrey Alan
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →